FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990516079> ?p ?o ?g. }

• W1990516079 endingPage "441" @default.
• W1990516079 startingPage "439" @default.
• W1990516079 abstract "To the Editor: An isolated antibody test for IgG antibody to hepatitis B core antigen (anti-HBc) is frequent in HIV-1–infected individuals, especially if they are coinfected with hepatitis C virus (HCV). 1–4 In a recent study, 42% of HIV-positive subjects who were negative for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B surface antigen (anti-HBs) were positive for anti-HBc. 5 This finding may represent resolved hepatitis B virus (HBV) infection with loss of anti-HBs, occult chronic HBV infection with loss of detectable HBsAg, or a false-positive result. Occult HBV infection is generally defined as a positive test for HBV DNA in a patient who has negative HBsAg and anti-HBs. 6 The frequency of hepatitis B viremia in patients with isolated anti-HBc is controversial. In a study of HIV-1–negative individuals with HCV infection, occult HBV infection was described in 33% of subjects and was more frequent in those with isolated anti-HBc. 7 In a study of HIV-1–infected subjects, HBV DNA was found in ∼60% of subjects with isolated anti-HBc. 8 However, in a recent study of 85 HIV-1–positive subjects with isolated anti-HBc, no patient was HBV DNA positive. 9 Thus, the relative contribution of occult hepatitis B viremia to the high frequency of isolated anti-HBc in patients with HIV-1 infection is still uncertain. We prospectively tested 84 HIV-1–infected individuals who were negative for HBsAg and anti-HBs for both anti-HBc and HBV DNA. To detect HBV DNA, we used an ultrasensitive assay (HBV TMA Assay; Gen-Probe, Inc., San Diego, CA). This qualitative test has demonstrated 95% detection of HBV DNA at ≥15 IU/mL (1 IU = 3–6 genome equivalent of HBV). This threshold of detection is much lower than those for many commercially available quantitative tests for HBV DNA (eg, the Hepatitis B Virus DNA Ultraquant test (Specialty Labs, Santa Monica, CA) measures values down to 0.01 pg/mL or ∼1500 copies/mL). Of 84 HIV-positive persons who were negative for HBsAg and anti-HBs, we found that 42 (50%) were positive for anti-HBc (isolated anti-HBc). Individuals coinfected with HIV and HCV were more likely to have isolated anti-HBc than were subjects with HIV infection alone (80% vs. 29%, respectively; P < 0.001). Subjects who were negative for anti-HBc had current and nadir CD4 cell counts similar to those of patients who had isolated anti-HBc (mean current CD4 cell count, 431 vs. 445/mm3, respectively; mean nadir CD4 cell count, 203 vs. 254/mm3, respectively; both comparisons not significantly different by the Wilcoxon rank sum test [Table 1]). In a multivariate model, isolated anti-HBc was associated with HCV antibody seropositivity but not with age, current and nadir CD4 cell counts, HIV-1 RNA level, or use of antiretroviral therapy (Table 2).TABLE 1: Risk Variables for HIV-Positive Subjects Who Tested Negative for Anti-HBs and HBsAgTABLE 2: Multivariate Analysis of Potential Risk Variables Associated with Isolated Anti-HBc in an HIV-1–Positive CohortThe 84 subjects were then tested for HBV DNA with an ultrasensitive assay. As expected, no subject who was negative for anti-HBc had detectable HBV DNA. Of 42 subjects positive for isolated anti-HBc, only 1 was positive for HBV DNA by ultrasensitive testing. This subject had documented HBV infection 7 years previously (HBsAg positive, anti-HBs positive), with subsequent loss of HBsAg and anti-HBs. Thus, the prevalence of HBV DNA positivity among this population of HIV-positive subjects with isolated anti-HBc was 2.4% (95% confidence interval, 0.06%–12%). The finding that 1 patient with documented previous hepatitis B infection had positive HBV DNA but negative HBsAg supports that idea that occult hepatitis B viremia may occur even after apparent clearance of infection (as judged by surface antigenemia). However, our study also shows that only a small proportion of HIV-positive subjects with isolated anti-HBc will have detectable HBV DNA using an ultrasensitive assay. There are several possible explanations for the low prevalence of HBV DNA among anti-HBc–positive subjects in this study. First, the level of hepatitis B viremia may have been lower than the threshold of detection of the assay used in this study. To address the issue of sensitivity, we used a qualitative assay with a threshold of detection much lower than those of quantitative assays used clinically. Second, a significant proportion of our subjects was receiving antiretroviral therapy that could affect HBV DNA levels: 50% were taking lamivudine, 4.8% were taking tenofovir, and 4.8% were taking tenofovir plus lamivudine. The average duration of use of ≥1 of these medications in our cohort was 32 months (range, 1–78 months). Although the rate of resistance to lamivudine is high (up to 20% after 12 months of use of the drug 10), use of this agent or tenofovir may have suppressed HBV levels in some patients. However, we also did not find HBV DNA in any of the subjects who were not receiving therapy that suppresses HBV. Finally, the low prevalence of HBV DNA among our cohort may be explained by the lack of ongoing occult infection with this virus. In conclusion, in HIV-positive individuals, isolated anti-HBc is common and is associated with HCV coinfection. Patients with HIV/HCV coinfection who do not have serologic evidence for HBV when screened with HBsAg and anti-HBs will be positive for anti-HBc in over three quarters of cases. A positive HBV DNA test is uncommon for HIV-positive subjects with isolated anti-HBc, even when an ultrasensitive qualitative assay is used. Thus, ongoing occult hepatitis B viremia in HIV-positive patients with isolated anti-HBc is rare. The implication of this finding for whether such individuals should be immunized against hepatitis B is under investigation. Rajesh T. Gandhi, MD Alysse Wurcel, BS Barbara McGovern, MD Hang Lee, PhD Janet Shopis, BS Colleen P. Corcoran, NP Sarah Toner, BS Christina Giachetti, PhD Janel Dockter Paul E. Sax, MD Chinweike Ukomadu, MD, PhD" @default.
• W1990516079 created "2016-06-24" @default.
• W1990516079 creator A5000473129 @default.
• W1990516079 creator A5015251444 @default.
• W1990516079 creator A5019255446 @default.
• W1990516079 creator A5019839561 @default.
• W1990516079 creator A5023002890 @default.
• W1990516079 creator A5025652958 @default.
• W1990516079 creator A5045529124 @default.
• W1990516079 creator A5062886212 @default.
• W1990516079 creator A5070324246 @default.
• W1990516079 creator A5074596928 @default.
• W1990516079 creator A5084363035 @default.
• W1990516079 date "2003-12-01" @default.
• W1990516079 modified "2023-10-11" @default.
• W1990516079 title "Low Prevalence of Ongoing Hepatitis B Viremia in HIV-Positive Individuals with Isolated Antibody to Hepatitis B Core Antigen" @default.
• W1990516079 cites W1579860441 @default.
• W1990516079 cites W2012324894 @default.
• W1990516079 cites W2018365340 @default.
• W1990516079 cites W2022056018 @default.
• W1990516079 cites W2031630426 @default.
• W1990516079 cites W2031960178 @default.
• W1990516079 cites W2046053558 @default.
• W1990516079 cites W2117941833 @default.
• W1990516079 cites W2145905144 @default.
• W1990516079 cites W2315619302 @default.
• W1990516079 doi "https://doi.org/10.1097/00126334-200312010-00013" @default.
• W1990516079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14615664" @default.
• W1990516079 hasPublicationYear "2003" @default.
• W1990516079 type Work @default.
• W1990516079 sameAs 1990516079 @default.
• W1990516079 citedByCount "26" @default.
• W1990516079 countsByYear W19905160792013 @default.
• W1990516079 countsByYear W19905160792014 @default.
• W1990516079 countsByYear W19905160792015 @default.
• W1990516079 countsByYear W19905160792016 @default.
• W1990516079 countsByYear W19905160792017 @default.
• W1990516079 countsByYear W19905160792018 @default.
• W1990516079 countsByYear W19905160792021 @default.
• W1990516079 crossrefType "journal-article" @default.
• W1990516079 hasAuthorship W1990516079A5000473129 @default.
• W1990516079 hasAuthorship W1990516079A5015251444 @default.
• W1990516079 hasAuthorship W1990516079A5019255446 @default.
• W1990516079 hasAuthorship W1990516079A5019839561 @default.
• W1990516079 hasAuthorship W1990516079A5023002890 @default.
• W1990516079 hasAuthorship W1990516079A5025652958 @default.
• W1990516079 hasAuthorship W1990516079A5045529124 @default.
• W1990516079 hasAuthorship W1990516079A5062886212 @default.
• W1990516079 hasAuthorship W1990516079A5070324246 @default.
• W1990516079 hasAuthorship W1990516079A5074596928 @default.
• W1990516079 hasAuthorship W1990516079A5084363035 @default.
• W1990516079 hasBestOaLocation W19905160791 @default.
• W1990516079 hasConcept C142724271 @default.
• W1990516079 hasConcept C147483822 @default.
• W1990516079 hasConcept C159047783 @default.
• W1990516079 hasConcept C159654299 @default.
• W1990516079 hasConcept C203014093 @default.
• W1990516079 hasConcept C204787440 @default.
• W1990516079 hasConcept C2522874641 @default.
• W1990516079 hasConcept C2776029263 @default.
• W1990516079 hasConcept C2776185481 @default.
• W1990516079 hasConcept C2777382497 @default.
• W1990516079 hasConcept C2777410769 @default.
• W1990516079 hasConcept C2778600374 @default.
• W1990516079 hasConcept C2780593183 @default.
• W1990516079 hasConcept C520017518 @default.
• W1990516079 hasConcept C71924100 @default.
• W1990516079 hasConceptScore W1990516079C142724271 @default.
• W1990516079 hasConceptScore W1990516079C147483822 @default.
• W1990516079 hasConceptScore W1990516079C159047783 @default.
• W1990516079 hasConceptScore W1990516079C159654299 @default.
• W1990516079 hasConceptScore W1990516079C203014093 @default.
• W1990516079 hasConceptScore W1990516079C204787440 @default.
• W1990516079 hasConceptScore W1990516079C2522874641 @default.
• W1990516079 hasConceptScore W1990516079C2776029263 @default.
• W1990516079 hasConceptScore W1990516079C2776185481 @default.
• W1990516079 hasConceptScore W1990516079C2777382497 @default.
• W1990516079 hasConceptScore W1990516079C2777410769 @default.
• W1990516079 hasConceptScore W1990516079C2778600374 @default.
• W1990516079 hasConceptScore W1990516079C2780593183 @default.
• W1990516079 hasConceptScore W1990516079C520017518 @default.
• W1990516079 hasConceptScore W1990516079C71924100 @default.
• W1990516079 hasIssue "4" @default.
• W1990516079 hasLocation W19905160791 @default.
• W1990516079 hasLocation W19905160792 @default.
• W1990516079 hasLocation W19905160793 @default.
• W1990516079 hasOpenAccess W1990516079 @default.
• W1990516079 hasPrimaryLocation W19905160791 @default.
• W1990516079 hasRelatedWork W1981834611 @default.
• W1990516079 hasRelatedWork W2028407039 @default.
• W1990516079 hasRelatedWork W2031526907 @default.
• W1990516079 hasRelatedWork W2039116125 @default.
• W1990516079 hasRelatedWork W2100920251 @default.
• W1990516079 hasRelatedWork W2323913969 @default.
• W1990516079 hasRelatedWork W2381644378 @default.
• W1990516079 hasRelatedWork W2776483213 @default.
• W1990516079 hasRelatedWork W2794227145 @default.
• W1990516079 hasRelatedWork W2796230093 @default.

• next